Overview of Dr. D'Angelo
Dr. Sandra D'Angelo is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. She received her medical degree from State University of New York Downstate Medical Center College of Medicine and has been in practice 13 years. Dr. D'Angelo accepts several types of health insurance, listed below. She is one of 494 doctors at Memorial Sloan Kettering Cancer Center and one of 90 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. She has more than 70 publications and over 500 citings.
Office
160 East 53rd Street
New York, NY 10022
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
NYU Grossman School of MedicineResidency, Internal Medicine, 2004 - 2007
State University of New York Downstate Medical Center College of MedicineClass of 2004
Certifications & Licensure
FL State Medical License 2021 - Present
NJ State Medical License 2019 - 2025
NY State Medical License 2005 - 2025
PA State Medical License 2024 - 2024- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma Start of enrollment: 2016 Dec 06
- Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma Start of enrollment: 2019 Aug 13
- Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma Start of enrollment: 2020 Sep 29
- Join now to see all
Publications & Presentations
PubMed
- 806 citationsPembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trialHussein Abdul-Hassan Tawbi, Melissa Amber Burgess, Vanessa Bolejack, Brian A. Van Tine, Scott M. Schuetze
The Lancet. Oncology. 2017-11-01 - 2014 citationsNivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phas...Jeffrey S. Weber, Sandra P. D'Angelo, David R. Minor, F. Stephen Hodi, Ralf Gutzmer
The Lancet. Oncology. 2015-04-01 - 73 citationsClinical genomic profiling in the management of patients with soft tissue and bone sarcoma.Mrinal M Gounder, Narasimhan P Agaram, Sally E Trabucco, Victoria Robinson, Richard A Ferraro
Nature Communications. 2022-06-15
Lectures
- Pilot study of NKTR214 and nivolumab in patients with sarcomas.2019 ASCO Annual Meeting - 6/1/2019
- Desmoid Tumors Biology: Exploiting Estrogen and Notch Signaling2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
- Pilot study of NY-ESO-1c259 T cells in advanced myxoid/round cell liposarcoma.2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Press Mentions
T-cell Therapy Shows Promise in Rare SarcomasNovember 12th, 2021
Immunotherapy Jumps Ahead of Chemotherapy in Advanced Merkel Cell CarcinomaApril 5th, 2019
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPOHumana ChoiceCare Network PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
